Safety and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Given with and without AS03 or MF59 Adjuvants in Healthy Adults

275 healthy adults, ages 19-64 years, were randomized to one of five groups to receive two doses of 15 µg unadjuvanted influenza A /H5N8 virus vaccine, or two doses of 7.5 or 15 µg of vaccine adjuvanted with AS03 or MF59.